HRP20170021T1 - Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol - Google Patents

Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol Download PDF

Info

Publication number
HRP20170021T1
HRP20170021T1 HRP20170021TT HRP20170021T HRP20170021T1 HR P20170021 T1 HRP20170021 T1 HR P20170021T1 HR P20170021T T HRP20170021T T HR P20170021TT HR P20170021 T HRP20170021 T HR P20170021T HR P20170021 T1 HRP20170021 T1 HR P20170021T1
Authority
HR
Croatia
Prior art keywords
cyclodextrin
composition according
ethyl
octylphenyl
diol
Prior art date
Application number
HRP20170021TT
Other languages
English (en)
Inventor
Supriya Rane
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45953284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20170021(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20170021T1 publication Critical patent/HRP20170021T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Claims (14)

1. Čvrsti farmaceutski sastav prikladan za oralnu primjenu, naznačen time, da obuhvaća sljedeće: a) prvi spoj odabran od 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diola, njegove farmaceutski prihvatljive soli, i njegovog fosfatnog derivata; b) punilo; i c) stabilizator koji sadrži ciklodekstrin ili njegov derivat; pri čemu fosfatni derivat ima sljedeću formulu: [image] gdje je ciklodekstrin ili njegov derivat prirodni ciklodekstrin, razgranati ciklodekstrin, alkil-ciklodekstrin ili hidroksialkil-ciklodekstrin, i pri čemu sastav sadrži manje od 0,5 mg prvog spoja.
[image] 2. Sastav prema zahtjevu 1, naznačen time, da punilo sadrži šećerni alkohol.
3. Sastav prema zahtjevu 2, naznačen time, da punilo sadrži manitol kao šećerni alkohol.
4. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da nadalje sadrži vezivo.
5. Sastav prema zahtjevu 4, naznačen time, da vezivo obuhvaća hidroksipropilcelulozu.
6. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da nadalje sadrži lubrikant.
7. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da ciklodekstrin ili njegov derivat je sljedeći: α-ciklodekstrin, β-ciklodekstrin, γ-ciklodekstrin, hidroksipropil-ciklodekstrin, sulfobutileter-β-ciklodekstrin, dodekakis-2,6,O-metil-α-ciklodekstrin, tetradekakis-2,6,O-metil-β-ciklodekstrin, heksadekakis-2,6,O-metil-γ-ciklodekstrin, tetradekakis-2,6,O-etil-β-ciklodekstrin, α-ciklodekstrin djelomično eteriziran s 2-hidroksipropilom, β-cklodekstrin djelomično eteriziran s 2-hidroksipropilom, razgranati α-ciklodekstrin ili razgranati β-ciklodekstrin, gdje se glukoza ili maltoza spaja preko α-1,6-glukozid-veze.
8. Sastav prema bilo kojem od zahtjeva 1 do 6, naznačen time, da stabilizator obuhvaća hidroksipropil-β-ciklodekstrin.
9. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da je stabilizator prisutan prema omjeru molarnog sadržaja, u količini od 0,4-puta do 3 puta od količine 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diola ili njegove farmaceutski prihvatljive soli.
10. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da prvi spoj je 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol ili njegova farmaceutski prihvatljiva sol.
11. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da se upotrebljava u liječenju autoimune bolesti.
12. Sastav prema zahtjevu 11, naznačen time, da autoimuna bolest je multipla skleroza.
13. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da je farmaceutski sastav u jediničnom doznom obliku, gdje svaka jedinica sadrži od 0,03 do 0,40 mg 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diola u slobodnom obliku, u obliku njegove farmaceutski prihvatljive soli i njegovog fosfatnog derivata koji ima sljedeću formulu: [image]
14. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da farmaceutski sastav je tableta ili kapsula.
HRP20170021TT 2011-04-01 2017-01-09 Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol HRP20170021T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161470747P 2011-04-01 2011-04-01
US201161545835P 2011-10-11 2011-10-11
EP12714163.8A EP2694037B1 (en) 2011-04-01 2012-03-30 Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
PCT/US2012/031340 WO2012135561A1 (en) 2011-04-01 2012-03-30 Formulations comprising 2 -amino- 2- [2- (4 - octylphenyl) ethyl] propane -1, 3 - diol

Publications (1)

Publication Number Publication Date
HRP20170021T1 true HRP20170021T1 (hr) 2017-03-10

Family

ID=45953284

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20170021TT HRP20170021T1 (hr) 2011-04-01 2017-01-09 Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol
HRP20200249TT HRP20200249T1 (hr) 2011-04-01 2020-02-14 Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20200249TT HRP20200249T1 (hr) 2011-04-01 2020-02-14 Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol

Country Status (35)

Country Link
US (5) US9592208B2 (hr)
EP (2) EP2694037B1 (hr)
JP (1) JP6019101B2 (hr)
KR (1) KR102027014B1 (hr)
CN (1) CN103476400B (hr)
AR (1) AR085749A1 (hr)
AU (1) AU2012236357B2 (hr)
BR (1) BR112013024430B1 (hr)
CA (1) CA2831600C (hr)
CL (1) CL2013002810A1 (hr)
CO (1) CO6771459A2 (hr)
CY (2) CY1118423T1 (hr)
DK (2) DK3143990T3 (hr)
EA (2) EA035686B1 (hr)
EC (1) ECSP13012912A (hr)
ES (2) ES2610966T3 (hr)
GT (1) GT201300227A (hr)
HK (1) HK1190309A1 (hr)
HR (2) HRP20170021T1 (hr)
HU (1) HUE031286T2 (hr)
IL (1) IL228250B (hr)
JO (1) JO3177B1 (hr)
LT (2) LT2694037T (hr)
MA (1) MA34981B1 (hr)
MX (1) MX342522B (hr)
MY (2) MY163746A (hr)
PE (2) PE20140162A1 (hr)
PL (2) PL2694037T3 (hr)
PT (2) PT2694037T (hr)
RS (1) RS59917B1 (hr)
SG (1) SG193256A1 (hr)
SI (2) SI2694037T1 (hr)
TW (1) TWI528958B (hr)
WO (1) WO2012135561A1 (hr)
ZA (1) ZA201306636B (hr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
CN103222966A (zh) * 2013-04-01 2013-07-31 北京万全德众医药生物技术有限公司 一种含有盐酸芬戈莫德的固体药物组合物及其制备方法
JP6316422B2 (ja) * 2013-07-29 2018-04-25 アイザント ドラッグ リサーチ ソリューションズ プライベート リミテッドAizant Drug Research Solutions Pvt Ltd フィンゴリモドの医薬組成物
CN106794159A (zh) * 2014-08-22 2017-05-31 广东东阳光药业有限公司 一种芬戈莫德固体组合物及其制备方法
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CN107530301A (zh) * 2015-01-20 2018-01-02 汉达医药有限责任公司 稳定的固体芬戈莫德剂型
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
ATE172711T1 (de) 1992-10-21 1998-11-15 Yoshitomi Pharmaceutical 2-amino-1, 3- propandiolverbindung und immunosuppressium
AU705320B2 (en) 1995-12-28 1999-05-20 Welfide Corporation 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof for use in the preparation of a non-oral medicament, and for treatment of diseases and disorders
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (ja) 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
AU735406B2 (en) 1997-02-27 2001-07-05 Novartis Ag Pharmaceutical composition
DE69825056T2 (de) 1997-04-04 2005-08-25 Mitsubishi Pharma Corp. 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森  昭 ウイルス性心筋炎の予防または治療薬剤
EP1315735A4 (en) 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
EP2316431B1 (en) * 2003-04-08 2015-09-30 Novartis AG Solid oral composition comprising a S1P receptor agonist and a sugar alcohol
JP4861177B2 (ja) * 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
WO2006063033A2 (en) 2004-12-06 2006-06-15 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
GB0502358D0 (en) * 2005-02-04 2005-03-16 Novartis Ag Organic compounds
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
LT3103448T (lt) * 2006-09-26 2019-10-10 Novartis Ag Farmacinės kompozicijos, apimančios s1p moduliatorių
WO2008079382A1 (en) 2006-12-21 2008-07-03 Abbott Laboratories Sphingosine-1 -phosphate receptor agonist and antagonist compounds
BRPI0818161B8 (pt) * 2007-10-12 2021-05-25 Novartis Ag mistura estável compreendendo agonista de receptores de s1p, sua forma de dosagem final e seu uso
MX2011004924A (es) 2008-11-11 2011-05-30 Novartis Ag Sales de fingolimod.
EA201100978A1 (ru) 2008-12-22 2012-01-30 Новартис Аг Схема приема агониста рецептора s1p

Also Published As

Publication number Publication date
LT3143990T (lt) 2020-02-25
KR102027014B1 (ko) 2019-09-30
ES2773482T3 (es) 2020-07-13
EP2694037A1 (en) 2014-02-12
BR112013024430A2 (pt) 2016-12-20
CN103476400A (zh) 2013-12-25
TWI528958B (zh) 2016-04-11
EP2694037B1 (en) 2016-10-12
PE20140162A1 (es) 2014-02-12
DK3143990T3 (da) 2020-03-02
SG193256A1 (en) 2013-10-30
CA2831600C (en) 2020-04-21
CY1118423T1 (el) 2017-06-28
EA201391442A1 (ru) 2014-04-30
GT201300227A (es) 2015-05-05
US20140371323A1 (en) 2014-12-18
AU2012236357A1 (en) 2013-10-10
PT2694037T (pt) 2017-01-17
AR085749A1 (es) 2013-10-23
MX2013011415A (es) 2013-12-09
LT2694037T (lt) 2017-01-10
RS59917B1 (sr) 2020-03-31
JO3177B1 (ar) 2018-03-08
US9592208B2 (en) 2017-03-14
EA027721B1 (ru) 2017-08-31
PL3143990T3 (pl) 2020-05-18
AU2012236357B2 (en) 2016-03-10
IL228250B (en) 2020-09-30
JP6019101B2 (ja) 2016-11-02
KR20140014194A (ko) 2014-02-05
MX342522B (es) 2016-10-03
MY163746A (en) 2017-10-31
DK2694037T3 (en) 2017-01-16
EP3143990B1 (en) 2019-11-27
HK1190309A1 (zh) 2014-07-04
ECSP13012912A (es) 2013-11-29
CN103476400B (zh) 2016-11-09
PE20170913A1 (es) 2017-07-12
CL2013002810A1 (es) 2014-02-14
TW201244711A (en) 2012-11-16
HUE031286T2 (hu) 2017-06-28
EP3143990A1 (en) 2017-03-22
US20180193291A1 (en) 2018-07-12
EA201790436A3 (ru) 2018-03-30
CO6771459A2 (es) 2013-10-15
CY1122868T1 (el) 2021-05-05
CA2831600A1 (en) 2012-10-04
NZ615023A (en) 2016-07-29
ZA201306636B (en) 2014-05-28
SI2694037T1 (sl) 2017-01-31
PL2694037T3 (pl) 2017-05-31
ES2610966T3 (es) 2017-05-04
EA035686B1 (ru) 2020-07-27
US20200276137A1 (en) 2020-09-03
MA34981B1 (fr) 2014-03-01
MY175633A (en) 2020-07-02
US20190247335A1 (en) 2019-08-15
PT3143990T (pt) 2020-03-04
HRP20200249T1 (hr) 2020-05-15
SI3143990T1 (sl) 2020-03-31
US20170135967A1 (en) 2017-05-18
JP2014509652A (ja) 2014-04-21
WO2012135561A1 (en) 2012-10-04
BR112013024430B1 (pt) 2022-02-08
EA201790436A2 (ru) 2017-10-31

Similar Documents

Publication Publication Date Title
HRP20170021T1 (hr) Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol
JP2013525501A5 (hr)
AU2011207103B2 (en) Anaesthetic formulation
Mosher et al. Complexation and cyclodextrins
KR102013718B1 (ko) Nsaid 및 사이클로덱스트린을 포함하는 신규한 약제학적 제제
CN104334164A (zh) 基于木糖醇的抗黏膜组合物以及相关方法和组合物
JP5823093B2 (ja) 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物
WO2008005819A2 (en) Ophthalmic formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20220387444A1 (en) Composition containing sulfoalkyl ether cyclodextrin and latanoprost
EA201370175A1 (ru) Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
JP2009531450A5 (hr)
UA107186C2 (xx) Тверді форми дозування бендамустину
RU2015102575A (ru) Жидкие композиции рацекадотрила
JP2014521641A5 (hr)
JP2019131596A5 (hr)
JP3597239B2 (ja) 安定な点眼剤
WO2018042363A1 (en) Pharmaceutical formulations of regadenoson
JP2018526420A5 (hr)
JP6239282B2 (ja) 腎不全改善剤
JP2011502169A5 (hr)
AU2013200895B2 (en) Anaesthetic formulation
JP2003199809A (ja) 軟カプセルシェル
JP2006117704A5 (hr)
CN101574524A (zh) 亲脂性药物磺烷基醚环糊精包合物及其制备方法
AU2014200491A1 (en) Anaesthetic formulation